ArticleInternational journal of molecular sciences2016
Pterostilbene Inhibits Human Multiple Myeloma Cells via ERK1/2 and JNK Pathway In Vitro and In Vivo.
Article in International journal of molecular sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 46 citations in OpenAlex.
- Pterostilbene in the Management and Treatment of Multiple Myeloma.Current issues in molecular biology · 2026Review
- Multiple myeloma inhibitory effects of natural compounds: enhancement through nanoparticle carriers.Frontiers in pharmacology · 2025Review
- Pterostilbene suppresses head and neck cancer cell proliferation via induction of apoptosis.Turkish journal of biology = Turk biyoloji dergisi · 2024Article
- Pterostilbene induces apoptosis in hepatocellular carcinoma cells: Biochemical, pathological, and molecular markers.Saudi journal of biological sciences · 2023Article
- New Insights into Dietary Pterostilbene: Sources, Metabolism, and Health Promotion Effects.Molecules (Basel, Switzerland) · 2022Review
- Active Components of Traditional Chinese Medicinal Material for Multiple Myeloma: Current Evidence and Future Directions.Frontiers in pharmacology · 2022Review
- Nanoparticles prepared from pterostilbene reduce blood glucose and improve diabetes complications.Journal of nanobiotechnology · 2021Article
- A novel phosphoramide compound, DCZ0805, shows potent anti-myeloma activity via the NF-κB pathway.Cancer cell international · 2021Article
- Review
- Pterostilbene in Cancer Therapy.Antioxidants (Basel, Switzerland) · 2021Review
- Pterostilbene promotes mitochondrial apoptosis and inhibits proliferation in glioma cells.Scientific reports · 2021Article
- Toxicological Evaluation of Piceatannol, Pterostilbene, and ε-Viniferin for Their Potential Use in the Food Industry: A Review.Foods (Basel, Switzerland) · 2021Review
- Pterostilbene inhibits gallbladder cancer progression by suppressing the PI3K/Akt pathway.Scientific reports · 2021Article
- Novel Small Molecular Compound AE-848 Potently Induces Human Multiple Myeloma Cell Apoptosis by Modulating the NF-κB and PI3K/Akt/mTOR Signaling Pathways.OncoTargets and therapy · 2020Article
- Pterostilbene inhibits lung squamous cell carcinoma growthOncology letters · 2019Article
- DCZ0814 induces apoptosis and G0/G1 phase cell cycle arrest in myeloma by dual inhibition of mTORC1/2.Cancer management and research · 2019Article
- [Emerging Actions of Pterostilebene on Cancer Research].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2018Review
- Pterostilbene inhibits nutrient metabolism and induces apoptosis through AMPK activation in multiple myeloma cells.International journal of molecular medicine · 2018Article
- Pterostilbene Suppresses Ovarian Cancer Growth via Induction of Apoptosis and Blockade of Cell Cycle Progression Involving Inhibition of the STAT3 Pathway.International journal of molecular sciences · 2018Article
- Apoptotic and Nonapoptotic Activities of Pterostilbene against Cancer.International journal of molecular sciences · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple myeloma (MM) is the second most common malignancy in the hematologic system, which is characterized by accumulation of plasma cells in bone marrow. Pterostilbene (PTE) is a natural dimethylated analog of resveratrol, which has anti-oxidant, anti-inflammatory and anti-tumor properties. In the present study, we examined the anti-tumor effect of PTE on MM cell lines both in vitro and in vivo using the cell counting kit (CCK)-8, apoptosis assays, cell cycle analysis, reactive oxygen species (ROS) generation, JC-1 mitochondrial membrane potential assay, Western blotting and tumor xenograft models. The results demonstrated that PTE induces apoptosis in the H929 cell line and causes cell cycle arrest at G0/G1 phase by enhancing ROS generation and reducing mitochondrial membrane potential. The anti-tumor effect of PTE may be caused by the activation of the extracellular regulated protein kinases (ERK) 1/2 and c-Jun N-terminal kinase (JNK) signaling pathways. Additionally, mice treated with PTE by intraperitoneal injection demonstrated reduced tumor volume. Taken together, the results of this study indicate that the anti-tumor effect of PTE on MM cells may provide a new therapeutic option for MM patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.